Literature DB >> 1350072

When does Parkinson's disease begin?

W C Koller1.   

Abstract

A long preclinical or asymptomatic period may occur in Parkinson's disease (PD). Many long-latency parkinsonian syndromes exist. The presence of early-life risk factors is consistent with a long prodromal period. Marked degeneration of the substantia nigra and loss of striatal dopamine are necessary before clinical symptoms develop. Lewy bodies, the histological hallmark of PD, occur in 10% of normal individuals over age 50. Clinical symptoms develop slowly and are often intermittent in early PD. Nonmotor signs, eg, depression or sensory changes, often precede motor signs by many years. Reduction of striatal dopamine can be detected with PET in "at-risk" asymptomatic individuals. Individual sensitivity to drug-induced parkinsonism also suggests a preclinical state. Biologic markers may eventually be able to detect preclinical PD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350072

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

Authors:  P K Morrish; J S Rakshi; D L Bailey; G V Sawle; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

Review 3.  How far are we in understanding the cause of Parkinson's disease?

Authors:  Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-07       Impact factor: 10.154

4.  Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

Authors:  Z Walker; D C Costa; A G Janssen; R W Walker; G Livingstone; C L Katona
Journal:  Eur J Nucl Med       Date:  1997-06

Review 5.  Pains in Parkinson disease--many syndromes under one umbrella.

Authors:  Gunnar Wasner; Günther Deuschl
Journal:  Nat Rev Neurol       Date:  2012-04-17       Impact factor: 42.937

6.  Physical activity and risk of Parkinson's disease: a prospective cohort study.

Authors:  G Logroscino; H D Sesso; R S Paffenbarger; I-M Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-08-22       Impact factor: 10.154

7.  Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine.

Authors:  Eric H Chudler; Ying Lu
Journal:  Brain Res       Date:  2008-04-08       Impact factor: 3.252

8.  Immediate effects of thermal-tactile stimulation on timing of swallow in idiopathic Parkinson's disease.

Authors:  Julie Regan; Margaret Walshe; W Oliver Tobin
Journal:  Dysphagia       Date:  2009-08-26       Impact factor: 3.438

9.  Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity.

Authors:  K J Schweitzer; S Behnke; I Liepelt; B Wolf; C Grosser; J Godau; A Gaenslen; T Bruessel; A Wendt; F Abel; A Müller; T Gasser; D Berg
Journal:  J Neural Transm (Vienna)       Date:  2007-04-20       Impact factor: 3.575

Review 10.  Nutrition and the risk for Parkinson's disease: review of the literature.

Authors:  Alexandra Gaenslen; Thomas Gasser; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.